Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma
Authors:
- Yige WuYWYige Wu
- Siqi ChenSCSiqi Chen
- Xiaolu YangXYXiaolu Yang
- Kazuhito SatoKSKazuhito Sato
- Preet LalPLPreet Lal
- Yuefan WangYWYuefan Wang
- Andrew T. ShinkleASAndrew T. Shinkle
- Michael C. WendlMWMichael C. Wendl
- Tina M. PrimeauTPTina M. Primeau
- Yanyan ZhaoYZYanyan Zhao
- Alanna GouldAGAlanna Gould
- Hua SunHSHua Sun
Open Access
- 27 September 2023
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 83 (24) , 4161-4178
Abstract
Current treatment approaches for renal cell carcinoma (RCC) face challenges in achieving durable tumor responses due to tumor heterogeneity and drug resistance. Combination therapies that leverage tumor molecular profiles could offer an avenue for enhancing treatment efficacy and addressing the limitations of current therapies. To identify effective strategies for treating RCC, we selected ten drugs guided by tumor biology to test in six RCC patient-derived xenograft (PDX) models. The multitargeted tyrosine kinase inhibitor (TKI) cabozantinib and mTORC1/2 inhibitor sapanisertib emerged as the most effective drugs, particularly when combined. The combination demonstrated favorable tolerability and inhibited tumor growth or induced tumor regression in all models, including two from patients who experienced treatment failure with FDA-approved TKI and immunotherapy combinations. In cabozantinib-treated samples, imaging analysis revealed a significant reduction in vascular density, and single-nucleus RNA sequencing (snRNA-seq) analysis indicated a decreased proportion of endothelial cells in the tumors. SnRNA-seq data further identified a tumor subpopulation enriched with cell-cycle activity that exhibited heightened sensitivity to the cabozantinib and sapanisertib combination. Conversely, activation of the epithelial–mesenchymal transition pathway, detected at the protein level, was associated with drug resistance in residual tumors following combination treatment. The combination effectively restrained ERK phosphorylation and reduced expression of ERK downstream transcription factors and their target genes implicated in cell-cycle control and apoptosis. This study highlights the potential of the cabozantinib plus sapanisertib combination as a promising treatment approach for patients with RCC, particularly those whose tumors progressed on immune checkpoint inhibitors and other TKIs.Significance: The molecular-guided therapeutic strategy of combining cabozantinib and sapanisertib restrains ERK activity to effectively suppress growth of renal cell carcinomas, including those unresponsive to immune checkpoint inhibitors.Keywords
All Related Versions
Funding Information
- National Cancer Institute (U54CA224083)
- National Institute of Diabetes and Digestive and Kidney Diseases (U01DK131380)
- National Institute of Allergy and Infectious Diseases (U54AG075934)
- National Cancer Institute (U54CA224076)
- National Cancer Institute (P30CA042014)
- National Cancer Institute (R01CA260112)
- National Cancer Institute (U2CCA223303)
This publication has 79 references indexed in Scilit:
- Insulin-like growth factor 2 mRNA-binding proteins (IGF2BPs): post-transcriptional drivers of cancer progression?Cellular and Molecular Life Sciences, 2012
- c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinomaAnnals of Oncology, 2012
- clusterProfiler: an R Package for Comparing Biological Themes Among Gene ClustersOMICS: A Journal of Integrative Biology, 2012
- Dual mTORC1/2 and HER2 Blockade Results in Antitumor Activity in Preclinical Models of Breast Cancer Resistant to Anti-HER2 TherapyClinical Cancer Research, 2012
- The translational landscape of mTOR signalling steers cancer initiation and metastasisNature, 2012
- VarScan 2: Somatic mutation and copy number alteration discovery in cancer by exome sequencingGenome Research, 2012
- Update on targeted therapies for clear cell renal cell carcinomaCurrent Opinion in Oncology, 2011
- RETRACTED: Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularizationProceedings of the National Academy of Sciences, 2009
- Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short readsBioinformatics, 2009
- External validation of IMP3 expression as an independent prognostic marker for metastatic progression and death for patients with clear cell renal cell carcinomaCancer, 2008